首页 > 最新文献

Alergologia Polska - Polish Journal of Allergology最新文献

英文 中文
Diagnostic and treatment trends in chronic urticaria. Retrospective and prospective analysis of patients from the Department of Dermatology, Medical University of Poznan 慢性荨麻疹的诊断和治疗趋势。波兹南医科大学皮肤科患者的回顾性和前瞻性分析
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.109382
A. Błaszczyk, D. Jenerowicz, F. Raciborski, A. Sadowska-Przytocka, Z. Adamski, M. Czarnecka-Operacz
{"title":"Diagnostic and treatment trends in chronic urticaria. Retrospective and prospective analysis of patients from the Department of Dermatology, Medical University of Poznan","authors":"A. Błaszczyk, D. Jenerowicz, F. Raciborski, A. Sadowska-Przytocka, Z. Adamski, M. Czarnecka-Operacz","doi":"10.5114/PJA.2021.109382","DOIUrl":"https://doi.org/10.5114/PJA.2021.109382","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rehabilitation of patients after COVID-19 COVID-19后患者康复
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.109380
Katarzyna Patlewicz, R. Pawliczak
The number of patients after COVID-19 keeps growing, and many of them have to face the long-term consequences of the disease, referred to as the,post-COVID syndrome". Due to the multitude of the symptoms alone as well as of the complications, the rehabilitation procedure must counteract those complications already taking place as well as prevent onset any future ones, so that the patient can be assured of restoration of the quality of their life the way it was before they fell ill with the disease at least. In order to develop an efficient rehabilitation model that could meet the current needs, at the same time taking into account the condition of healthcare, analyzed has been the hitherto research as well as the observations conducted, basing it all on the already systematized acquis of the rehabilitation circle.
2019冠状病毒病后的患者人数不断增加,其中许多人不得不面对疾病的长期后果,即“后冠状病毒综合征”。由于大量的症状和并发症,康复过程必须抵消那些已经发生的并发症,并防止任何未来的发作,这样病人就可以保证恢复他们的生活质量,至少是他们生病之前的生活质量。为了开发一种能够满足当前需求的高效的康复模式,同时考虑到医疗保健状况,在康复界已经系统化的成果的基础上,对迄今为止的研究和观察进行了分析。
{"title":"Rehabilitation of patients after COVID-19","authors":"Katarzyna Patlewicz, R. Pawliczak","doi":"10.5114/PJA.2021.109380","DOIUrl":"https://doi.org/10.5114/PJA.2021.109380","url":null,"abstract":"The number of patients after COVID-19 keeps growing, and many of them have to face the long-term consequences of the disease, referred to as the,post-COVID syndrome\". Due to the multitude of the symptoms alone as well as of the complications, the rehabilitation procedure must counteract those complications already taking place as well as prevent onset any future ones, so that the patient can be assured of restoration of the quality of their life the way it was before they fell ill with the disease at least. In order to develop an efficient rehabilitation model that could meet the current needs, at the same time taking into account the condition of healthcare, analyzed has been the hitherto research as well as the observations conducted, basing it all on the already systematized acquis of the rehabilitation circle.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of two currently available anti-COVID-19 vaccines 目前两种抗covid -19疫苗的比较
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.102554
R. Pawliczak
At the end of 2020, the all-over-the-world vaccination against COVID-19 programs have been launched Currently in Poland we have two vaccines available In this short review we are trying to compare them, based on available literature data This may help physicians and patients All parties should have in mind that this data are limited by time and number of exposed, so it will be changing while the vaccinated population is growing
在2020年底,针对COVID-19的全球疫苗接种计划已经启动。目前在波兰,我们有两种疫苗可用。在这篇简短的综述中,我们试图根据现有的文献数据对它们进行比较。这可能有助于医生和患者。所有各方都应该记住,这些数据受时间和暴露数量的限制,因此随着接种疫苗的人口的增长,它会发生变化
{"title":"Comparison of two currently available anti-COVID-19 vaccines","authors":"R. Pawliczak","doi":"10.5114/PJA.2021.102554","DOIUrl":"https://doi.org/10.5114/PJA.2021.102554","url":null,"abstract":"At the end of 2020, the all-over-the-world vaccination against COVID-19 programs have been launched Currently in Poland we have two vaccines available In this short review we are trying to compare them, based on available literature data This may help physicians and patients All parties should have in mind that this data are limited by time and number of exposed, so it will be changing while the vaccinated population is growing","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Recommendations of the Polish Society of Allergology on the qualification of person with allergies and anaphylaxis to vaccination against COVID-19 波兰过敏症学会关于过敏和过敏反应者接种COVID-19疫苗资格的建议
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.104220
J. Kruszewski, E. Cichocka-Jarosz, E. Czarnobilska, M. Jutel, M. Kulus, P. Kuna, M. Kupczyk, M. Niedoszytko, M. Nittner-Marszalska, C. Pałczyński, B. Rogala, B. Samoliński, R. Spiewak, Justyna Zajdel-Całkowska
Recommendations of the Polish Society of Allergology regarding the qualification of person with allergies and anaphylaxis for vaccination against COVID-19 were presented, both for doctors qualifying for vaccination against COVID-19 who are not allergologists and for allergologists consulting patients with a history of anaphylaxis or severe (uncontrolled) allergic diseases and asthma vaccinated against COVID-19
波兰过敏症学会提出了关于过敏和过敏反应患者接种COVID-19疫苗资格的建议,包括有资格接种COVID-19疫苗的非过敏科医生,以及有过敏反应史或严重(不受控制的)过敏性疾病和哮喘患者的过敏科医生
{"title":"Recommendations of the Polish Society of Allergology on the \u0000qualification of person with allergies and anaphylaxis to vaccination against COVID-19","authors":"J. Kruszewski, E. Cichocka-Jarosz, E. Czarnobilska, M. Jutel, M. Kulus, P. Kuna, M. Kupczyk, M. Niedoszytko, M. Nittner-Marszalska, C. Pałczyński, B. Rogala, B. Samoliński, R. Spiewak, Justyna Zajdel-Całkowska","doi":"10.5114/PJA.2021.104220","DOIUrl":"https://doi.org/10.5114/PJA.2021.104220","url":null,"abstract":"Recommendations of the Polish Society of Allergology regarding the qualification of person with allergies and anaphylaxis for vaccination against COVID-19 were presented, both for doctors qualifying for vaccination against COVID-19 who are not allergologists and for allergologists consulting patients with a history of anaphylaxis or severe (uncontrolled) allergic diseases and asthma vaccinated against COVID-19","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Cases of anaphylaxis after the Comirnaty© vaccine and promotion of allergy epidemic are unfavourable for the National Vaccination Programme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic 接种Comirnaty©疫苗后的过敏反应病例和促进过敏流行对国家疫苗接种规划不利——流行病学专家小组和国家过敏症顾问的建议是不现实的
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.104654
M. Kurek
No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears
没有过敏反应病例的临床试验注册Pfizer-BioNTech 12月和现代化mRNA疫苗大规模疫苗接种程序实现了在英国和美国在美国K两个过敏发作后注册的第一剂量mRNA辉瑞疫苗被两个女人与已知的食品和药物过敏至少十几集已报告在美国也是猜测,过敏反应的发生率因对于与辉瑞疫苗相关的前两次过敏事件,MHRA排除了任何在食物、药物或疫苗后有过敏史的人。在美国,CDC排除了任何有与任何疫苗成分相关的严重或立即过敏反应史的人。我们认为,这种说法背后的理由过于模糊,这些预防措施也过于极端。唯一应该采取的安全措施是在全球、国家和个人层面进行疫苗后监测,可获得适当的参考点如下:在波兰,疫苗接种计划于12月底启动。12月26日,我们的流行病学专家小组提出了建议。不幸的是,这些只是MHRA和CDC预防措施的汇编。国家过敏症顾问的建议于12月28日提出,而不是排除所有有食物,药物,或疫苗,每次发作后建议特别注意,要求过敏症专科医生检测对Comirnaty©疫苗所有成分的致敏性,事实上这是不现实的,在波兰,这些物质无法用于常规诊断。不幸的是,过敏和药物不良反应的全球统一术语很少受到学者和过敏症专科医生的尊重。这扰乱了医生的逻辑推理,增加了病人的恐惧
{"title":"Cases of anaphylaxis after the Comirnaty© vaccine and promotion \u0000of allergy epidemic are unfavourable for the National Vaccination \u0000Programme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic","authors":"M. Kurek","doi":"10.5114/PJA.2021.104654","DOIUrl":"https://doi.org/10.5114/PJA.2021.104654","url":null,"abstract":"No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Statement of Polish Respiratory Society and Polish Society of Allergology on the treatment of pulmonary complications in patients after SARS-CoV-2 infection 波兰呼吸学会和波兰过敏症学会关于SARS-CoV-2感染后肺部并发症治疗的声明
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/pja.2021.109379
W. Piotrowski, A. Barczyk, A. Chciałowski, J. Chorostowska-Wynimko, M. Czajkowska-Malinowska, A. Kania, M. Kupczyk, K. Sładek, M. Kulus, P. Śliwiński
The aim of this document is to provide physicians treating patients with a history of COVID-19 pneumonia with recommendations on proper diagnostics and management of respiratory sequelae associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The expert panel provides 32 recommendations with respect to the treatment of lung consequences (including antibiotic therapy, corticosteroid therapy, and antithrombotic prophylaxis and treatment), pulmonary rehabilitation, lung transplantation, patient monitoring, and ambulatory settings. The management of patients with respiratory comorbidities (asthma, chronic obstructive pulmonary disease, lung cancer, and interstitial lung disease) and the medications used for treatment of these conditions, such as corticosteroids and antifibrotic drugs, is discussed. Presented recommendations are based on the most recent reports and aimed at providing patients post-COVID-19 respiratory sequelae with optimal standards of care.
本文件旨在为治疗有COVID-19肺炎病史的医生提供关于正确诊断和管理与严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染相关的呼吸道后遗症的建议。专家小组就肺部后果的治疗(包括抗生素治疗、皮质类固醇治疗和抗血栓预防和治疗)、肺康复、肺移植、患者监测和门诊设置提供了32项建议。讨论了呼吸合并症(哮喘、慢性阻塞性肺病、肺癌和间质性肺疾病)患者的管理以及用于治疗这些疾病的药物,如皮质类固醇和抗纤维化药物。提出的建议以最新报告为基础,旨在为covid -19后呼吸道后遗症患者提供最佳护理标准。
{"title":"Statement of Polish Respiratory Society and Polish Society of Allergology on the treatment of pulmonary complications in patients after SARS-CoV-2 infection","authors":"W. Piotrowski, A. Barczyk, A. Chciałowski, J. Chorostowska-Wynimko, M. Czajkowska-Malinowska, A. Kania, M. Kupczyk, K. Sładek, M. Kulus, P. Śliwiński","doi":"10.5114/pja.2021.109379","DOIUrl":"https://doi.org/10.5114/pja.2021.109379","url":null,"abstract":"The aim of this document is to provide physicians treating patients with a history of COVID-19 pneumonia with recommendations on proper diagnostics and management of respiratory sequelae associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The expert panel provides 32 recommendations with respect to the treatment of lung consequences (including antibiotic therapy, corticosteroid therapy, and antithrombotic prophylaxis and treatment), pulmonary rehabilitation, lung transplantation, patient monitoring, and ambulatory settings. The management of patients with respiratory comorbidities (asthma, chronic obstructive pulmonary disease, lung cancer, and interstitial lung disease) and the medications used for treatment of these conditions, such as corticosteroids and antifibrotic drugs, is discussed. Presented recommendations are based on the most recent reports and aimed at providing patients post-COVID-19 respiratory sequelae with optimal standards of care.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between house dust mites and environmental factors beyond the analysis power of a skin prick test 室内尘螨与环境因素的关系超出了皮肤点刺试验的分析能力
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/PJA.2021.106687
S. Kılıç, M. M. Cicekliyurt, Sibel Oymak Yalçın
{"title":"The relationship between house dust mites \u0000and environmental factors beyond the analysis power \u0000of a skin prick test","authors":"S. Kılıç, M. M. Cicekliyurt, Sibel Oymak Yalçın","doi":"10.5114/PJA.2021.106687","DOIUrl":"https://doi.org/10.5114/PJA.2021.106687","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multisystem inflammatory syndrome in children – allergist and immunologist point of view 儿童多系统炎症综合征——过敏症专家和免疫学家的观点
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/pja.2021.111796
A. Sybilski
Multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C) is a complication following SARS-CoV-2 infection. It may appear a few weeks after coronavirus infection, even if it was asymptomatic. Symptoms may appear gradually in the following days of illness and may be mild to severe in its course. The most common symptoms of MIS-C include fever > 3 days, gastrointestinal symptoms, skin changes. Shock can often occur. The key pathomechanism of the syndrome is hyperinflammation and an altered cytokine profile. Activation of T lymphocytes in MIS-C is mediated by the superantigen, which is the spike protein of the virus. The clinical picture and the immune pathophysiological profile show similarities between MIS-C and Kawasaki diseases (KD). The relationship of MIS-C with allergic diseases has not been investigated, but by analogy it can be assumed that it will be similar to KD. Allergic rhinitis, asthma, and atopic dermatitis have been demonstrated to increase following KD. Children who have previously suffered from combined allergic diseases (atopic dermatitis, allergic rhinitis, and urticaria) are at an increased risk of developing KD. There is an increased risk of KD in children who had sought medical care for allergic diseases more than twice a year compared to children with fewer medical visits. Data on the relationship of KD with atopy indicate the need to undertake studies analyzing MIS-C in this context.
与COVID-19相关的儿童多系统炎症综合征(MIS-C)是SARS-CoV-2感染后的并发症。它可能在冠状病毒感染后几周出现,即使没有症状。症状可在发病后几天逐渐出现,病程可由轻至重。MIS-C最常见的症状包括发烧3天,胃肠道症状,皮肤变化。休克是经常发生的。该综合征的关键病理机制是过度炎症和细胞因子谱的改变。MIS-C中T淋巴细胞的激活是由超抗原介导的,超抗原是病毒的刺突蛋白。临床表现和免疫病理生理特征显示misc和川崎病(KD)的相似之处。MIS-C与变应性疾病的关系尚未研究,但通过类比可以推测其与KD相似。变应性鼻炎、哮喘和特应性皮炎已被证实在KD后增加。以前患有合并过敏性疾病(特应性皮炎、过敏性鼻炎和荨麻疹)的儿童患KD的风险增加。与就诊次数较少的儿童相比,每年因过敏性疾病就诊两次以上的儿童患KD的风险增加。KD与特应性关系的数据表明有必要在此背景下进行分析MIS-C的研究。
{"title":"Multisystem inflammatory syndrome in children – allergist and immunologist point of view","authors":"A. Sybilski","doi":"10.5114/pja.2021.111796","DOIUrl":"https://doi.org/10.5114/pja.2021.111796","url":null,"abstract":"Multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C) is a complication following SARS-CoV-2 infection. It may appear a few weeks after coronavirus infection, even if it was asymptomatic. Symptoms may appear gradually in the following days of illness and may be mild to severe in its course. The most common symptoms of MIS-C include fever > 3 days, gastrointestinal symptoms, skin changes. Shock can often occur. The key pathomechanism of the syndrome is hyperinflammation and an altered cytokine profile. Activation of T lymphocytes in MIS-C is mediated by the superantigen, which is the spike protein of the virus. The clinical picture and the immune pathophysiological profile show similarities between MIS-C and Kawasaki diseases (KD). The relationship of MIS-C with allergic diseases has not been investigated, but by analogy it can be assumed that it will be similar to KD. Allergic rhinitis, asthma, and atopic dermatitis have been demonstrated to increase following KD. Children who have previously suffered from combined allergic diseases (atopic dermatitis, allergic rhinitis, and urticaria) are at an increased risk of developing KD. There is an increased risk of KD in children who had sought medical care for allergic diseases more than twice a year compared to children with fewer medical visits. Data on the relationship of KD with atopy indicate the need to undertake studies analyzing MIS-C in this context.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new dimension of the lipid transfer protein syndrome – attention to sex, drugs and alcohol 脂质转移蛋白综合征的新维度——对性、药物和酒精的关注
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/pja.2021.111797
K. Buczyłko
{"title":"A new dimension of the lipid transfer protein syndrome – attention to sex, drugs and alcohol","authors":"K. Buczyłko","doi":"10.5114/pja.2021.111797","DOIUrl":"https://doi.org/10.5114/pja.2021.111797","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Isolated allergic conjunctivitis 孤立性过敏性结膜炎
IF 0.2 Pub Date : 2021-01-01 DOI: 10.5114/pja.2021.106684
E. Mrukwa-Kominek, Julia Janiszewska-Salamon, Agnieszka Urgacz-Lechowicz, Wojciech Luboń, R. Gawlik
{"title":"Isolated allergic conjunctivitis","authors":"E. Mrukwa-Kominek, Julia Janiszewska-Salamon, Agnieszka Urgacz-Lechowicz, Wojciech Luboń, R. Gawlik","doi":"10.5114/pja.2021.106684","DOIUrl":"https://doi.org/10.5114/pja.2021.106684","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alergologia Polska - Polish Journal of Allergology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1